Harrow, Inc. (NASDAQ:HROW) Short Interest Update

Harrow, Inc. (NASDAQ:HROW - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 3,490,000 shares, a decline of 14.5% from the September 30th total of 4,080,000 shares. Based on an average daily volume of 588,600 shares, the days-to-cover ratio is currently 5.9 days.

Institutional Trading of Harrow

A number of large investors have recently modified their holdings of HROW. Hills Bank & Trust Co acquired a new stake in Harrow in the 3rd quarter valued at approximately $107,000. Rice Hall James & Associates LLC grew its stake in shares of Harrow by 23.1% in the third quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company's stock worth $14,157,000 after purchasing an additional 59,019 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Harrow by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company's stock valued at $307,000 after purchasing an additional 2,668 shares during the period. Semanteon Capital Management LP bought a new stake in shares of Harrow during the third quarter valued at about $686,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock worth $57,000 after purchasing an additional 227 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Performance

HROW stock traded down $0.65 during midday trading on Tuesday, reaching $46.55. The company had a trading volume of 594,179 shares, compared to its average volume of 497,825. The firm has a market capitalization of $1.65 billion, a PE ratio of -48.22 and a beta of 0.75. The stock has a 50 day moving average price of $46.08 and a 200 day moving average price of $29.02. Harrow has a fifty-two week low of $7.60 and a fifty-two week high of $59.23. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $48.94 million during the quarter, compared to the consensus estimate of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. Analysts anticipate that Harrow will post 0.09 earnings per share for the current year.

Wall Street Analyst Weigh In

HROW has been the subject of a number of analyst reports. Lake Street Capital upped their price objective on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. Craig Hallum boosted their price objective on Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a report on Friday, October 4th. Finally, B. Riley reiterated a "buy" rating and issued a $50.00 target price on shares of Harrow in a research report on Thursday, August 29th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.